米洛沙星的抗菌活性。
Antibacterial activity of miloxacin.
作者信息
Izawa A, Kisaki Y, Irie K, Eda Y, Nakagome T, Komatsu T
出版信息
Antimicrob Agents Chemother. 1980 Jul;18(1):37-40. doi: 10.1128/AAC.18.1.37.
The chemotherapeutic properties of miloxacin (5,8-dihydro-5-methoxy-8-oxo-2H-1,3-dioxolo-[4,5-g]quinoline-7-carboxylic acid) have been compared with those of oxolinic acid and nalidixic acid. The in vitro activities of miloxacin (minimum inhibitory concentrations) against a variety of gram-negative bacteria, especially Enterobacteriaceae and Haemophilus, were comparable to those of oxolinic acid and 8 to 16 times greater than those of nalidixic acid. Miloxacin was more active than oxolinic acid against some anaerobes and less active against staphylococci. Miloxacin exhibited significant activities when administered orally to mice infected with Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Proteus vulgaris, or Serratia marcescens. Its efficacy was comparable to that of oxolinic acid and two to four times greater than that of nalidixic acid. Miloxacin was less active against a Pseudomonas aeruginosa infection and inactive at the maximum test doses against a Streptococcus pyogenes infection.
已将米洛沙星（5,8 - 二氢 - 5 - 甲氧基 - 8 - 氧代 - 2H - 1,3 - 二氧杂环戊烯并[4,5 - g]喹啉 - 7 - 羧酸）的化疗特性与恶喹酸和萘啶酸的化疗特性进行了比较。米洛沙星对多种革兰氏阴性菌，尤其是肠杆菌科细菌和嗜血杆菌的体外活性（最低抑菌浓度）与恶喹酸相当，比萘啶酸高8至16倍。米洛沙星对某些厌氧菌的活性比恶喹酸高，对葡萄球菌的活性较低。给感染大肠杆菌、肺炎克雷伯菌、奇异变形杆菌、普通变形杆菌或粘质沙雷氏菌的小鼠口服米洛沙星时，它表现出显著活性。其疗效与恶喹酸相当，比萘啶酸高两到四倍。米洛沙星对铜绿假单胞菌感染的活性较低，在最大测试剂量下对化脓性链球菌感染无活性。
Zotero 插件